Paper Details

  1. Home
  2. Paper Details

Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.

Author: BigalkeHans, DresslerDirk

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the risk of BT-B-AB-induced therapy failure in patients who were exposed to botulinum toxin for the first time. Four out of nine patients experienced complete therapy failure.
Paper Details　
Original Abstract of the Article :
Botulinum toxin induced therapy failure type B antibody (BT-B, BT-B-AB) has so far only been reported after previous formation of antibodies against botulinum toxin type A (BT-A, BTA- AB). We wanted to explore the risk of BT-B-AB-induced therapy failure in patients who were exposed to botulinum toxi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00415-005-0774-3

データ提供：米国国立医学図書館（NLM）

Botulinum Toxin Type B: Navigating the Challenges of Therapy Failure

Botulinum toxin type B is a neurotoxin used to treat conditions like cervical dystonia. This study investigates the risk of therapy failure due to the formation of antibodies against botulinum toxin type B in patients receiving this treatment for the first time.

Antibody-Induced Therapy Failure: A Significant Concern

The study found that 44% of patients experienced complete therapy failure due to antibody formation against botulinum toxin type B. This highlights the significant risk of antibody-induced therapy failure in patients receiving botulinum toxin type B treatment.

Understanding Antibody Formation: A Key to Effective Treatment

This study emphasizes the importance of understanding and managing antibody formation against botulinum toxin type B. Further research is needed to identify strategies for preventing or mitigating antibody-induced therapy failure.

Dr. Camel's Conclusion

The use of botulinum toxin type B, like navigating a desert with shifting sands, can be unpredictable. This study sheds light on the potential challenges of antibody-induced therapy failure. As researchers continue to explore this complex terrain, we can strive to create more effective and reliable treatments for conditions like cervical dystonia.

Date :
  1. Date Completed 2006-01-04
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

15761672

DOI: Digital Object Identifier

10.1007/s00415-005-0774-3

Related Literature

Article Analysis
・Side Effects of rimabotulinumtoxinb injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.